temsirolimus
Selected indexed studies
- Temsirolimus. (Recent Results Cancer Res, 2014) [PMID:24756806]
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. (Lancet, 2016) [PMID:26673811]
- Temsirolimus. (Drugs Today (Barc), 2007) [PMID:17987219]
_Worker-drafted node — pending editorial review._
Connections
temsirolimus is a side effect of
Sources
- Temsirolimus. (2014) pubmed
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. (2016) pubmed
- Temsirolimus. (2007) pubmed
- Temsirolimus. (2010) pubmed
- Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. (2024) pubmed
- Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. (2017) pubmed
- A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. (2018) pubmed
- Temsirolimus metabolic pathways revisited. (2020) pubmed
- Temsirolimus: a safety and efficacy review. (2012) pubmed
- Temsirolimus: In relapsed and/or refractory mantle cell lymphoma. (2010) pubmed